Kinase inhibitors are enzymes which selectively block the action of other enzymes. They help in regulation of the activity of other proteins and, more indirectly, the activities of cells. All these kinases can be divided by amino acids in which phosphorylation is inhibited. Since they can control or regulate the activities of other cells, they are often used in the treatment of cancer and inflammatory conditions.
Download exclusive Sample of this report:
Due to the rise in the incidence of cancer patients globally, kinase inhibitors are being considered to be of potential help in prevention of proliferation of these cancerous cells. Most of the drugs in clinical trials and those that are expected to be launched in recent years are based on the kinase inhibition activity of these drugs.
The kinase inhibitors market is expected to see a staggering growth with the current market valued at USD 15 billion in 2012 and anticipated to reach USD 36 billion in 2018 with a CAGR of 8 to 9 % from 2012 to 2018.
View exclusive Global strategic Business report :
Exponential growth is projected due to a rise in the incidence of various cancers, rise in aging population and increased focus of pharmaceutical companies on R&D to come up with potential medicines for treatment of cancers. Healthcare cost containment issues and cuts in research funding are the major setbacks for the growth of this market.
Competition to launch newer products, which would accelerate sales revenues has propelled the major players to focus on the growth of kinase inhibitors. For instance Novartis’s Gleevec for treatment of leukemia is amongst the best-selling kinase inhibitor drugs.
Some of the major players in this market are AstraZeneca, GlaxoSmithKline (GSK), Bayer, Novartis, and Roche and Pfizer. U.S., Japan, and Europe remain the major markets, however, rise in incidence of cancer and disposable income in emerging countries like India and China are gaining attention from these pharmaceutical players.